{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.3","upperLimit":"59.5","value":"50"},{"groupId":"OG001","lowerLimit":"47.5","upperLimit":"68.8","value":"58.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is defined as a \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"NUMBER","populationDescription":"Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.","reportingStatus":"POSTED","timeFrame":"Up to Week 16","title":"Disease Control Rate at 16 Weeks (DCR16) Per BICR","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}